{"log_id": 4505171751758041985, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 1e-06, "average": 0.999041, "min": 0.997276}, "location": {"width": 95, "top": 221, "height": 28, "left": 210}, "words": "免疫原性"}, {"probability": {"variance": 7e-06, "average": 0.998835, "min": 0.98603}, "location": {"width": 739, "top": 277, "height": 37, "left": 256}, "words": "与所有治疗性蛋白相似,在接受本品治疗的患者中可能出现免疫应答。免疫"}, {"probability": {"variance": 1e-06, "average": 0.99915, "min": 0.993756}, "location": {"width": 787, "top": 312, "height": 36, "left": 209}, "words": "原性数据反映了在免疫试验中,试验结果提示本品抗体阳性的患者百分比,并高"}, {"probability": {"variance": 0, "average": 0.99926, "min": 0.998026}, "location": {"width": 322, "top": 350, "height": 33, "left": 208}, "words": "度依赖于试验的灵敏度和特异性"}, {"probability": {"variance": 2.7e-05, "average": 0.998606, "min": 0.96978}, "location": {"width": 741, "top": 408, "height": 35, "left": 254}, "words": "在不同治疗组中,本品免疫反应性的治疗前发生率为0%~5%。每月注射"}, {"probability": {"variance": 1e-06, "average": 0.999239, "min": 0.994422}, "location": {"width": 681, "top": 441, "height": 37, "left": 208}, "words": "本品,为期6至24个月后,大约1%至8%的患者中可检出本品抗体"}, {"probability": {"variance": 7e-06, "average": 0.998645, "min": 0.987139}, "location": {"width": 753, "top": 502, "height": 35, "left": 243}, "words": "目前,对本品的免疫反应性的临床显著意义尚且不明。在免疫反应性水平最"}, {"probability": {"variance": 4e-06, "average": 0.998827, "min": 0.989101}, "location": {"width": 752, "top": 537, "height": 36, "left": 207}, "words": "高的新生血管性年龄相关的黄斑变性患者中,部分可出现虹膜炎或玻璃体炎"}, {"probability": {"variance": 1e-06, "average": 0.998695, "min": 0.997052}, "location": {"width": 81, "top": 603, "height": 29, "left": 215}, "words": "【禁忌】"}, {"probability": {"variance": 1e-06, "average": 0.999169, "min": 0.995971}, "location": {"width": 460, "top": 662, "height": 34, "left": 253}, "words": "对本品或本品成份中任何一种辅料过敏者禁用"}, {"probability": {"variance": 5e-06, "average": 0.998295, "min": 0.992821}, "location": {"width": 389, "top": 723, "height": 32, "left": 253}, "words": "活动的或怀疑的眼部或眼周感染的患者"}, {"probability": {"variance": 1e-06, "average": 0.999201, "min": 0.99691}, "location": {"width": 228, "top": 786, "height": 29, "left": 254}, "words": "活动期眼内炎症的患者"}, {"probability": {"variance": 0, "average": 0.999541, "min": 0.998628}, "location": {"width": 128, "top": 849, "height": 27, "left": 214}, "words": "【注意事项】"}, {"probability": {"variance": 3e-06, "average": 0.998834, "min": 0.990817}, "location": {"width": 728, "top": 904, "height": 34, "left": 254}, "words": "玻璃体内注射,包括本品注射,与眼内炎、眼内感染、孔源性视网膜脱离"}, {"probability": {"variance": 0.000433, "average": 0.99267, "min": 0.890271}, "location": {"width": 787, "top": 937, "height": 36, "left": 210}, "words": "视网膜撕裂和医源性外伤性白内障有关(参见【不良反应】)。本品注射时必须采"}, {"probability": {"variance": 1.4e-05, "average": 0.998274, "min": 0.979322}, "location": {"width": 789, "top": 972, "height": 35, "left": 207}, "words": "用合格的无菌注射技术。此外,注射后一周内应监测患者的情况,从而早期发现"}, {"probability": {"variance": 4e-06, "average": 0.998704, "min": 0.990371}, "location": {"width": 788, "top": 1006, "height": 35, "left": 207}, "words": "感染并治疗。应指导患者在出现任何提示有眼内炎的症状或任何上述提到的事件"}, {"probability": {"variance": 4.2e-05, "average": 0.997117, "min": 0.977838}, "location": {"width": 230, "top": 1044, "height": 29, "left": 207}, "words": "时,应立即报告给医生"}, {"probability": {"variance": 0, "average": 0.744289, "min": 0.744289}, "location": {"width": 115, "top": 1030, "height": 61, "left": 946}, "words": " CRMACEUT"}, {"probability": {"variance": 0.05178, "average": 0.735686, "min": 0.42886}, "location": {"width": 104, "top": 1067, "height": 38, "left": 910}, "words": "德土(中"}, {"probability": {"variance": 0.001642, "average": 0.987953, "min": 0.786101}, "location": {"width": 839, "top": 1070, "height": 72, "left": 251}, "words": "本品注射后60分钟内可观察到眼内压升高(参见【不良反应。因此须同"}, {"probability": {"variance": 2e-06, "average": 0.999035, "min": 0.993823}, "location": {"width": 570, "top": 1136, "height": 34, "left": 207}, "words": "时对眼内压和视神经乳头的血流灌注进行监测和适当治疗"}, {"probability": {"variance": 0.000236, "average": 0.979572, "min": 0.962952}, "location": {"width": 86, "top": 1125, "height": 44, "left": 940}, "words": "限公司"}, {"probability": {"variance": 1e-06, "average": 0.999067, "min": 0.996046}, "location": {"width": 744, "top": 1199, "height": 29, "left": 254}, "words": "玻璃体内使用血管内皮生长因子(VEGF)抑制剂后,存在潜在的动脉血栓"}, {"probability": {"variance": 2e-05, "average": 0.99791, "min": 0.97555}, "location": {"width": 787, "top": 1230, "height": 36, "left": 209}, "words": "栓塞事件的风险。在临床Ⅲ期研究中,动脉血栓栓塞事件的发生率在本品和对"}, {"probability": {"variance": 0.000308, "average": 0.992617, "min": 0.89747}, "location": {"width": 788, "top": 1265, "height": 33, "left": 208}, "words": "照组之间是相近的。接受本品0.5mg的患者与本品0.3mg或对照相比,卒中的发"}, {"probability": {"variance": 0.005705, "average": 0.985444, "min": 0.545694}, "location": {"width": 791, "top": 1298, "height": 37, "left": 207}, "words": "生率在数值上较高,不过此差异并无统计学显著性。卒中率的差异在具有已知卒"}, {"probability": {"variance": 1.5e-05, "average": 0.998228, "min": 0.97789}, "location": {"width": 787, "top": 1332, "height": 36, "left": 210}, "words": "中风险因子的患者,包括既往卒中病史或短暂性脑缺血发作史的患者中更大。因"}, {"probability": {"variance": 1e-06, "average": 0.999372, "min": 0.99636}, "location": {"width": 788, "top": 1366, "height": 37, "left": 206}, "words": "此主治医生应对这些患者谨慎评价本品治疗是否合适,以及治疗益处是否超过了"}, {"probability": {"variance": 1e-06, "average": 0.999202, "min": 0.998188}, "location": {"width": 117, "top": 1408, "height": 26, "left": 208}, "words": "潜在的风险"}, {"probability": {"variance": 0, "average": 0.99958, "min": 0.997993}, "location": {"width": 548, "top": 1463, "height": 33, "left": 255}, "words": "与所有治疗用蛋白质药物一样,本品有潜在的免疫原性"}], "language": 3}